GlaxoSmithKline Scientists Brush Up on Sales Pitches

Every so often, an update appears on how GlaxoSmithKline is faring with its so-called DPUs. These are known inside the drugmaker as drug performance units and were formed in 2008 to prompt the R&D folks to think differently about their budgets, goals and performance (back story). The upshot: every three years, they make a pitch for funds from the overall R&D treasury, and now the second cycle is about to begin.

Back to news